Insulin regulation of CIDEA and CIDEC via Akt1/2 and JNK2
anti-phospho-Akt (Ser473), anti-phospho-Akt (Thr308), anti-JNK, anti-phospho-JNK, and anti-phospho-c-Jun antibodies were purchased from Cell Signaling Technology (Beverly, MA). Antic-Jun antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Differentiation of human preadipocytes into adipocytes
Human preadipocytes, derived from subcutaneous adipose tissue of six female subjects, were obtained from Zen-Bio (Research Triangle Park, NC). Institutional approval was obtained for the study and all participants gave their informed consent. The patients were nonsmokers with a mean body mass index of 27.9 (range 25.7-29.9) and an average age of 40 years (range, 29-52 years). Human preadipocytes were differentiated into adipocytes as described previously ( 45 ) . Human preadipocytes were seeded on 24-well plates and cultured in DMEM/F-12 medium with 10% FBS, 100 units/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin B at 37°C under an atmosphere of 5% CO 2 . Cells were grown to confl uence and treated with differentiation medium consisting of DMEM/F-12 medium containing 3% FBS, 500 M 3-isobutyl-1-methylxanthine, 1 M rosiglitazone, 100 nM insulin, 1 M Dex, 33 M biotin, 17 M pantothenate, 100 units/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin B for 6 days. Cells were then cultured in maintenance medium consisting of DMEM/F-12 medium containing 3% FBS, 100 nM insulin, 1 M Dex, 33 M biotin, 17 M pantothenate, 100 units/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin B for 5 days. Cells were treated again with differentiation medium for 6 days, and then cultured in maintenance medium for 2 days. These cells were used as differentiated adipocytes in all experiments. The medium was changed for fresh medium every 3 days in all cases.
Quantitative real-time PCR
Total RNA was isolated and treated with DNase using an RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Total RNA (100-200 ng) was reverse transcribed to cDNA in 20 l reactions using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Quantitative gene expression analysis was performed on an ABI 7500 Fast instrument (Applied Biosystems) by TaqMan gene expression assay. Gene expression levels were normalized relative to 18S rRNA and are shown as the mRNA levels relative to control. PCR was performed using Hs00154455_m1 for CIDEA, Hs00535723_m1 for CIDEC, Hs00178289_m1 for Akt1, Hs00609846_m1for Akt2, Hs00178533_m1 for Akt3, Hs00177083_m1 for JNK1, Hs00177102_m1 for JNK2, and Hs99999901_s1 for 18S rRNA (Applied Biosystems).
siRNA study
Differentiated adipocytes were transfected with 10 nM control siRNA (12935-110; Invitrogen), Akt1 siRNA (12935-001 Duplex1; Invitrogen), Akt2 siRNA (12937-40 Duplex2; Invitrogen), Akt3 siRNA (HSS115177; Invitrogen), JNK1 siRNA (12936-42 Duplex1; Invitrogen), or JNK2 siRNA (12936-44 Duplex1; Invitrogen) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. Transfection was performed once 5 days prior to the assays.
Western blot analysis
Western blot analysis was performed as described previously ( 45 ) . Total cell lysates were prepared with a lysis buffer containing 25 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS, 50 mM sodium fl uoride, 2.5 mM sodium pyrophosphate, 1 mM ␤ -glycerophosphate, On the other hand, the three major MAPKs, i.e., extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, also contribute to the actions of insulin ( 22 ) and are associated with obesity and insulin resistance (23) (24) (25) (26) . The JNK subtypes are encoded by three genes. JNK1 and JNK2 are expressed ubiquitously, and they play key roles in the development of obesity and insulin resistance ( 24, 25 ) . JNK3 is expressed mainly in the brain, heart, and testis ( 27 ) , and it is an important component in the pathogenesis of neurotoxicity ( 28 ) . These JNK isoforms mediate cell proliferation, apoptosis in various cell types ( 29, 30 ) , and lipid droplet metabolism in adipocytes ( 31 ) .
The cell death-inducing DNA fragmentation factor-␣ -like effector (CIDE) family, i.e., CIDEA, CIDEB, and CIDEC (CIDE-3 or fat-specifi c protein 27), was identifi ed initially as a group of factors that induces apoptosis in mammalian cells ( 32, 33 ) . Recent studies using mice defi cient in CIDE proteins suggested that this class of protein is closely related to energy balance and obesity (34) (35) (36) (37) . In addition, lower levels of CIDEA in human WAT are observed in abdominal obesity, enlarged fat cells, and insulin resistance ( 38, 39 ) . Polymorphism of CIDEA and CIDEC is associated with human obesity and partial lipodystrophy (40) (41) (42) . CIDEC is localized around the lipid droplets in adipocytes and plays an important role in lipid droplet formation ( 43, 44 ) . Furthermore, we recently showed that insulin decreases CIDEA and increases CIDEC expression in human adipocytes and the differential regulation of these genes is related, at least in part, to insulin-induced anti-apoptosis and lipid droplet formation ( 45 ) . These results suggest that downregulation of CIDEA and upregulation of CIDEC by insulin in human adipocytes contribute to the actions of insulin and may play key roles in the development of obesity.
However, the upstream mechanisms by which insulin differentially regulates CIDEA and CIDEC expression remain unclear. In this study, we investigated signaling molecules involved in insulin regulation of CIDEA and CIDEC in human adipocytes. Here, we show that PI3K mediates both CIDEA and CIDEC regulation by insulin and that Akt1/2 and JNK2 mediate the insulin regulation of CIDEA and CIDEC, which are related to insulin-induced anti-apoptosis and lipid droplet formation, respectively, in human adipocytes.
MATERIALS AND METHODS

Materials
DMEM/F-12 (1:1, v/v) was purchased from Invitrogen (Carlsbad, CA). Human insulin was purchased from Novo Nordisk (Bagsvaerd, Denmark), and rosiglitazone was purchased from Alexis Biochemicals (San Diego, CA). 3-Isobutyl-1-methylxanthine, dexamethasone (Dex), and pantothenate were purchased from Sigma (St. Louis, MO). Biotin was purchased from Wako Pure Chemical Industries (Osaka, Japan), and FBS was purchased from Biological Industries (Kibbutz Beit Haemek, Israel). Wortmannin, PI-103, API-2, U0126, SP600125, and SB203580 were purchased from Calbiochem (San Diego, CA). Mouse anti-human CIDEA monoclonal antibody (H00001149-M01) and mouse anti-human CIDEC polyclonal antibody (H00063924-B01P) were purchased from Abnova Corporation (Taipei, Taiwan). Anti-Akt, for 5 min at room temperature, and washed three times. After the fi nal washes, cells were mounted on slides with ProLong Gold Antifade Reagent (Invitrogen) and visualized by confocal laser microscopy (LSM 700; Carl Zeiss, Jena, Germany). Photomicrographs were captured under green (TUNEL), blue (DAPI), and red (Nile 1 mM sodium orthovanadate, and complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The cell lysates were centrifuged at 17800 g for 10 min at 4°C. The supernatants were separated on 10-15% SDS-polyacrylamide gels and transferred onto Immobilon-P membranes (Millipore Corporation, Bedford, MA). Membranes were blocked for 1 h with 5% BSA in TBS with 0.05% Tween-20 and incubated overnight at 4°C with antibodies specifi c to CIDEA, CIDEC, Akt, phospho-Akt (Ser473), phospho-Akt (Thr308), JNK, phospho-JNK, c-Jun, and phospho-c-Jun. The blots were then treated with horseradish peroxidase-conjugated anti-rabbit IgG antibody (GE Healthcare, Little Chalfont, Buckinghamshire, UK) for 1 h. Proteins were visualized using ECL detection reagents (GE Healthcare).
Analysis of apoptosis
Analysis of apoptosis was performed as described previously ( 45 ) . Preadipocytes were grown and differentiated into adipocytes on glass coverslips as described above. Differentiated adipocytes were incubated in serum/Dex-free maintenance medium in the presence or absence of 100 nM insulin for 48 h. After treatment, the cells were fi xed with 2% paraformaldehyde in PBS for 20 min at room temperature and washed once with PBS, followed by permeabilization with 0.2% Triton X-100 in 0.1% sodium citrate for 10 min on ice. After fi xation, cells were incubated in terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) reaction mixture for 60 min at 37°C. Cells were then washed, incubated with 0.2 g/ml 4 ′ ,6 ′ -diamidino-2-phenylindole (DAPI; Sigma) and 0.1 g/ml Nile Red (Sigma) in PBS Differentiated adipocytes were starved in serum/Dex/insulin-free maintenance medium for 16 h. Cells were then treated with wortmannin or PI-103 at the indicated concentrations for 30 min followed by stimulation with or without 100 nM insulin for 24 h. The mRNA expression levels of CIDEA and CIDEC were measured by quantitative real-time PCR, normalized relative to 18S rRNA expression, and shown as relative mRNA levels. Data are presented as means ± SEM of three independent experiments. * P < 0.05, ** P < 0.01 versus control without insulin; ## P < 0.01 versus control with insulin.
Fig. 2.
The Akt inhibitor API-2 and the JNK inhibitor SP600125 selectively block regulation of CIDEA and CIDEC expression by insulin, respectively. A: Concentration-response effect of the Akt inhibitor on CIDEA and CIDEC mRNA expression. Differentiated adipocytes were starved in serum/Dex/insulin-free maintenance medium for 16 h. Cells were then treated with API-2 at the indicated concentrations for 30 min followed by stimulation with or without 100 nM insulin for 24 h. B: Effects of the MAPK inhibitors on CIDEA and CIDEC mRNA expression. Differentiated adipocytes were starved in serum/Dex/ insulin-free maintenance medium for 16 h. Cells were then treated with 10 U0126, 10 SP600125, or 20 SB203580 for 30 min followed by stimulation with or without 100 nM insulin for 24 h. C: Concentration-response effect of the JNK inhibitor on CIDEC mRNA expression. Differentiated adipocytes were starved in serum/Dex/ insulin-free maintenance medium for 16 h. Cells were then treated with SP600125 at the indicated concentrations for 30 min followed by stimulation with or without 100 nM insulin for 24 h. The mRNA expression levels of CIDEA and CIDEC were measured by quantitative real-time PCR, normalized relative to 18S rRNA expression, and shown as relative mRNA levels. Data are presented as means ± SEM of three independent experiments. * P < 0.05, ** P < 0.01 versus control without insulin; Red) channels at 20× magnifi cation and merged using ImageJ software (http://rsb.info.nih.gov/ij/). Apoptotic adipocytes were triple-stained with TUNEL, DAPI, and Nile Red, and apoptosis was quantifi ed by counting the number of triple-stained cells. To- Fig. 3 . Depletion of both Akt1 and Akt2 enhances insulin-reduced CIDEA expression. A and B: Differentiated adipocytes were treated with control siRNA (siControl), Akt1 siRNA (siAkt1), Akt2 siRNA (siAkt2), and/or Akt3 siRNA (siAkt3) in maintenance medium for 7 days. Cells were then starved in serum/Dex/insulin-free maintenance medium for 16 h followed by stimulation with or without 100 nM insulin for 24 h. The mRNA expression levels of CIDEA (A), Akt1, Akt2, and Akt3 (B) were measured by quantitative real-time PCR, normalized relative to 18S rRNA expression, and shown as relative mRNA levels. Data are presented as means ± SEM of three independent experiments. ** P < 0.01 versus siControl without insulin; ## P < 0.01 versus siControl with insulin. C: Western blot analysis of CIDEA protein expression. Differentiated adipocytes were treated with control siRNA or Akt1/2 siRNA in maintenance medium for 7 days. Cells were then starved in serum/Dex/insulin-free maintenance medium for 16 h followed by stimulation with or without 100 nM insulin for 48 h. ␤ -Actin served as a loading control. These experiments were performed three times, and the results of one representative experiment are shown. D: Quantifi cation of protein expression levels of CIDEA. The protein expression levels of CIDEA were normalized relative to ␤ -actin protein expression and shown as relative protein levels. Data are presented as means ± SEM of three independent experiments. * P < 0.01 versus siControl without insulin; 
RESULTS
Insulin regulates CIDEA and CIDEC expression via a PI3K-dependent pathway
To investigate whether regulation of CIDEA and CIDEC by insulin in human adipocytes is mediated by PI3K, differentiated adipocytes were treated with the PI3K inhibitors wortmannin or PI-103 followed by stimulation with or without insulin. Wortmannin and PI-103 blocked both insulininduced downregulation of CIDEA and upregulation of CIDEC expression in a concentration-dependent manner ( Fig. 1A , B ) . These results suggest that the regulation of CIDEA and CIDEC expression by insulin in human adipocytes is mediated via a PI3K-dependent signaling pathway.
Akt and JNK selectively mediate insulin regulation of CIDEA and CIDEC, respectively
We next examined the contributions of Akt and MAPK pathways to the regulation of CIDEA and CIDEC expression by insulin. Differentiated adipocytes were treated with the Akt inhibitor API-2, which suppresses growth factor-induced phosphorylation of Akt1, Akt2, and Akt3 ( 46 ), the MAPK/ERK kinase inhibitor U0126, the JNK inhibitor SP600125, or the p38 inhibitor SB203580 followed by TUNEL assay was performed using an in situ cell death detection kit (Roche) according to the manufacturer's instructions.
Analysis of lipid droplet size
Cells were fi xed and stained with Nile Red as described above. Cells were photographed at 63× magnifi cation, and the size of Nile Red-stained lipid droplets was calculated using ImageJ software (100 lipid droplets in 10 random fi elds examined).
Measurement of glycerol release
Measurement of glycerol release was performed as described previously ( 45 ) . Differentiated adipocytes were starved in serum/Dex/ insulin-free maintenance medium for 16 h and then incubated in serum/Dex-free maintenance medium in the presence or absence of insulin for 24 h. After incubation, the medium was collected, and glycerol contents were measured using free glycerol reagent (Sigma) according to the manufacturer's instructions. The results were corrected for cellular proteins, which were quantifi ed using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL), and are expressed as micrograms of glycerol per milligram of protein.
Statistical analyses
The signifi cance of differences was assessed by unpaired t -test. In all analyses, P < 0.05 was taken to indicate statistical significance. Data are expressed as the means ± SEM of three independent experiments. 2B ). In contrast, SP600125 blocked the effects of insulin on CIDEC expression, whereas U0126 and SB203580 did not ( Fig. 2B ) . SP600125 also inhibited insulin-induced upregulation of CIDEC in a concentration-dependent manner ( Fig. 2C ) . These results suggest that the regulatory stimulation with or without insulin. API-2 blocked insulininduced downregulation of CIDEA in a concentrationdependent manner, but it did not affect insulin-induced upregulation of CIDEC ( Fig. 2A ) . The MAPK inhibitors did not alter the effects of insulin on CIDEA expression ( Fig.   Fig. 5 . Depletion of JNK2, but not JNK1, attenuates insulin-induced CIDEC expression. A and B: Differentiated adipocytes were treated with control siRNA (siControl), JNK1 siRNA (siJNK1), and/or JNK2 siRNA (siJNK2) in maintenance medium for 7 days. Cells were then starved in serum/Dex/insulin-free maintenance medium for 16 h followed by stimulation with or without 100 nM insulin for 24 h. The mRNA expression levels of CIDEC (A), JNK1, and JNK2 (B) were measured by quantitative real-time PCR, normalized relative to 18S rRNA expression, and shown as relative mRNA levels. Data are presented as means ± SEM of three independent experiments. ** P < 0.01 versus siControl without insulin; ## P < 0.01 versus 10 nM siControl with insulin; § § P < 0.01 versus 20 nM siControl with insulin. C: Western blot analysis of CIDEC protein expression. Differentiated adipocytes were treated with control siRNA or JNK2 siRNA in maintenance medium for 7 days. Cells were then starved in serum/Dex/insulin-free maintenance medium for 16 h followed by stimulation with or without 100 nM insulin for 48 h. ␤ -Actin served as a loading control. These experiments were performed three times, and the results of one representative experiment are shown. D: Quantifi cation of protein expression levels of CIDEC. The protein expression levels of CIDEC were normalized relative to ␤ -actin protein expression and shown as relative protein levels. Data are presented as means ± SEM of three independent experiments. ** P < 0.01 versus siControl without insulin; ## P < 0.01 versus 10 nM siControl with insulin. reduced by insulin ( Fig. 3C, D ) . These results suggest that insulin-induced downregulation of CIDEA is mediated by both Akt1 and Akt2 in human adipocytes. We next investigated the contributions of Akt to the anti-apoptotic actions of insulin in human adipocytes. Combined treatment with Akt1/2 siRNA restored apoptosis reduced by insulin ( Fig. 4A , B ) . These results indicate that insulin-induced inhibition of apoptosis is mediated by both Akt1 and Akt2 in human adipocytes.
JNK2, but not JNK1, is required for insulin-induced upregulation of CIDEC and enlargement of lipid droplets
To further verify the specifi c involvement of JNK in insulin regulation of CIDEC, differentiated adipocytes were treated with JNK1 and/or JNK2 siRNA, and then stimulated with or without insulin. JNK1 siRNA alone had no effect on CIDEC expression, whereas either treatment with JNK2 siRNA alone or combined treatment with JNK1/2 siRNA similarly attenuated CIDEC expression induced by insulin ( Fig. 5A ) . Each siRNA-mediated knockdown resulted in specifi c reductions in the levels of JNK1 and JNK2 mRNAs, respectively ( Fig. 5B ) . Furthermore, JNK2 siRNA attenuated CIDEC protein levels induced by insulin ( Fig. 5C, D ) .
To investigate the roles of JNK in insulin-induced lipid droplet formation in human adipocytes, differentiated adipocytes were treated with siRNA in the presence or absence of insulin. Insulin-induced enlargement of lipid droplets was markedly inhibited by JNK2 but not JNK1 siRNA ( Fig. 6A , B ) . These results indicate that insulininduced upregulation of CIDEC and enlargement of lipid droplets require JNK2 but not JNK1 in human adipocytes.
PI3K mediates insulin-induced phosphorylation of Akt and JNK
To confi rm whether Akt and JNK act downstream of PI3K in human adipocytes, we examined the effects of PI3K inhibitors on Akt and JNK phosphorylation. Time course study showed that insulin induced Akt Ser473, Akt Thr308, and JNK phosphorylation ( Fig. 7A ). Akt and JNK phosphorylation, which were apparent 30 min after initiation of insulin treatment, were prevented by treatment with either wortmannin or PI-103 ( Fig. 7B ) . Furthermore, API-2 and SP600125 did not affect insulin-induced phosphorylation of JNK and Akt, respectively, suggesting that neither Akt nor JNK activation may be required for modulation of each other by insulin ( Fig. 7C, D ) . These results suggest that insulin-induced phosphorylation of Akt and JNK is mediated via a PI3K-dependent pathway in human adipocytes.
DISCUSSION
We recently reported that differential gene regulation of CIDEA and CIDEC by insulin contributes to insulininduced anti-apoptosis and lipid droplet formation in human adipocytes. The results of the present study provided the fi rst evidence regarding the signaling pathways involved effects of insulin on CIDEA and CIDEC expression are selectively mediated by Akt and JNK, respectively, in human adipocytes.
Both Akt1 and Akt2 mediate insulin-induced downregulation of CIDEA and inhibition of apoptosis
To further verify the specifi c involvement of Akt in insulin regulation of CIDEA, experiments using siRNA-mediated gene suppression of Akt1, Akt2, and/or Akt3 were performed. Differentiated adipocytes were treated with siRNA and then stimulated with or without insulin. Treatment with Akt1, Akt2, or Akt3 siRNA alone did not affect insulin-induced downregulation of CIDEA (data not shown). In contrast, combined treatment with Akt1/2 siRNA recovered CIDEA mRNA levels reduced by insulin by 61%, whereas Akt1/3 or Akt2/3 did not affect the CI-DEA mRNA levels ( Fig. 3A ) . Each siRNA-mediated knockdown resulted in specifi c reductions in the levels of Akt1, Akt2, and Akt3 mRNAs, respectively ( Fig. 3B ) . Furthermore, Akt1/2 siRNA enhanced CIDEA protein levels that Akt1/2 mediates insulin-induced inhibition of apoptosis in human adipocytes ( Fig. 4 ) . Consistent with our results, it has been reported that combined loss of Akt1/2 causes increased apoptosis after stimulation in thymocytes ( 20 ) . Inhibition of Akt signaling induces apoptosis in 3T3-L1 adipocytes ( 48 ) . These results suggest that Akt1/2 contributes to the anti-apoptotic effect of insulin and the effect of insulin via Akt1/2 is mediated at least in part by downregulation of CIDEA in human adipocytes. Future studies will be required to clarify the precise contribution of CIDEA to the anti-apoptotic effect of insulin via Akt1/2.
On the other hand, inhibition of JNK, but not Akt, ERK, or p38, selectively blocked insulin-induced upregulation of CIDEC ( Fig. 2 ) . The JNK inhibitor SP600125, which inhibits both JNK1 and JNK2 with similar potency ( 49 ) , blocked the effects of insulin on CIDEC expression in a concentration-dependent manner ( Fig. 2C ) . Interestingly, depletion of JNK2 or JNK1/2 similarly attenuated insulininduced upregulation of CIDEC, whereas JNK1 depletion did not ( Fig. 5 ) . These results indicated that insulininduced upregulation of CIDEC requires JNK2, but not JNK1. As our previous fi ndings suggested that CIDEC contributes to insulin-induced enlargement of lipid droplets ( 45 ), we investigated the role of JNK in lipid droplet in insulin-mediated regulation of CIDEA and CIDEC in human adipocytes. PI3K inhibitors blocked both insulininduced downregulation of CIDEA and upregulation of CIDEC ( Fig. 1 ) . Upregulation of CIDEC by insulin by PI3K was consistent with previous reports in mouse 3T3-L1 adipocytes ( 47 ) . These results suggest that the regulatory effects of insulin on both CIDEA and CIDEC expression are mediated via a PI3K-dependent pathway.
We next examined the contributions of Akt, a key target of PI3K, and MAPK to regulation of CIDEA and CIDEC expression by insulin. Inhibition of Akt, but not ERK, JNK, or p38, by specifi c inhibitors selectively blocked insulininduced downregulation of CIDEA ( Fig. 2 ) . Although siRNA-mediated depletion of Akt1/3 or Akt2/3 did not affect the regulatory effects of insulin on CIDEA expression, Akt1/2 depletion prevented insulin-induced downregulation of CIDEA expression ( Fig. 3 ) . These results suggest that insulin-induced downregulation of CIDEA is mediated by both Akt1 and Akt2, which may play overlapping roles in the insulin regulation of CIDEA. As our previous fi ndings suggested that CIDEA contributes to insulin-induced inhibition of apoptosis ( 45 ), we investigated the role of Akt in apoptosis. Depletion of Akt1/2 by siRNA restored apoptosis reduced by insulin, suggesting We also showed that insulin induces JNK phosphorylation via the PI3K pathway, which is the fi rst such evidence reported to date in human adipocytes. Insulin has been shown to stimulate Akt and JNK activation via PI3K in other cells ( 14, 54, 55 ) . Consistent with these results, insulin stimulated both Akt and JNK phosphorylation in human adipocytes ( Fig. 7A ) . The PI3K inhibitors abrogated both Akt and JNK phosphorylation induced by insulin ( Fig. 7B ) . These results suggest that PI3K mediates insulininduced activation of Akt and JNK in human adipocytes. Insulin also induced c-Jun phosphorylation in human adipocytes (supplementary Fig. II) . It has been demonstrated that c-Jun is a major substrate for JNK and regulates transcription of multiple genes responsive to the hormone ( 56 ) . It will be very important to verify signals, such as cJun, between JNK and CIDEC in future studies.
In conclusion, the present study provides the fi rst evidence that Akt1/2 and JNK2, which act downstream of PI3K, selectively mediate regulation of CIDEA and CIDEC expression by insulin, respectively, in human adipocytes. We speculate that CIDEA and CIDEC are differentially regulated by insulin via different signaling pathways and, thus, contribute separately to insulin-induced anti-apoptosis and lipid droplet formation ( Fig. 8 ). These fi ndings reinforce our observations regarding the roles of insulin in regulating the physiological functions of human adipocytes. Furthermore, the identifi cation of novel signaling pathways mediating insulin regulation of CIDEA and CI-DEC will provide additional targets for the development of effective therapeutic strategies to combat obesity and its associated disorders.
formation. Depletion of JNK2, but not JNK1, inhibited insulin-induced enlargement of lipid droplets ( Fig. 6 ) . This is the fi rst report indicating that JNK2, but not JNK1, is required for insulin-induced lipid droplet formation in human adipocytes. Taken together, these results suggest that JNK2 is involved in insulin-mediated regulation of CI-DEC, which plays a critical role in lipid droplet formation. siRNA screening revealed that JNK2 is a regulator of lipid droplet homeostasis in HeLa cells ( 50 ) . JNK1 but not JNK2 defi ciency resulted in reduced adiposity and increased insulin sensitivity in mouse models of obesity ( 24 ) . However, mice with the phenotype JNK1 +/ Ϫ JNK2 Ϫ / Ϫ , but not JNK1 +/ Ϫ JNK2 +/+ , were resistant to diet-induced obesity and insulin resistance, suggesting that JNK2 is involved in metabolic regulation ( 25 ) . These observations implied a role of JNK2 in lipid-related pathologies, such as obesity and insulin resistance.
A recent study showed that insulin regulates adipocyte lipolysis via an Akt-independent but PI3K-dependent signaling pathway in rodents ( 51 ) . Therefore, we examined lipolysis in human adipocytes treated with JNK1 or JNK2 siRNA. Consistent with previous studies ( 45, 52 ) , insulin did not affect the basal levels of glycerol release (supplementary Fig. I ). Depletion of neither JNK1 nor JNK2 affected glycerol release in either the presence or absence of insulin, suggesting that the observed effects of JNK2 depletion on insulin-induced lipid droplet formation may not be related to lipolysis. It has been shown that CIDEC stabilization is associated with triacylglycerol synthesis and lipid droplet formation ( 53 ) . Thus, insulin-induced lipid droplet formation via a JNK2-dependent pathway may be related not to lipolysis but to triacylglycerol synthesis and accompanying regulation of CIDEC expression. However, the mechanism is unclear, and further studies are required to explain these observations. Supplemental Material can be found at:
